Acorah Software Products - Accounts Production19.4.351truetruefalsetrueNo description of principal activity1 November 202430 November 202530 November 202516055042Mr. Assaad Rayessiso4217:GBPiso4217:EURiso4217:USDxbrli:sharesxbrli:purexbrli:pure160550422024-10-31160550422025-11-30160550422024-11-012025-11-3016055042frs-bus:PrivateLimitedCompanyLtd2024-11-012025-11-3016055042frs-bus:FilletedAccounts2024-11-012025-11-3016055042frs-bus:Micro-entities2024-11-012025-11-3016055042frs-bus:EntityHasNeverTraded2024-11-012025-11-3016055042frs-bus:AuditExempt-NoAccountantsReport2024-11-012025-11-3016055042frs-bus:Director12024-11-012025-11-30
Registered number: 16055042
Ray Pharma Limited
Unaudited Financial Statements
For the Period 1 November 2024 to 30 November 2025
Ray Pharma Limited
Balance Sheet
As At 30 November 2025
Balance Sheet
Registered number: 16055042
30 November 2025
£
Current assets
100
NET CURRENT ASSETS
100
TOTAL ASSETS LESS CURRENT LIABILITIES
100
NET ASSETS
100
CAPITAL AND RESERVES
100
Notes
1.General Information
Ray Pharma Limited is a private company, limited by shares, incorporated in England & Wales, registered number 16055042. The registered office is First Floor, 244 Edgware Road, London, W2 1DS.
2.Average Number of Employees
Average number of employees, including directors, during the period was: NIL
-
Page 0
Page 1
Ray Pharma Limited
Balance Sheet (continued)
As At 30 November 2025
For the period ending 30 November 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.